GLP-1 receptor agonists as a pharmacological class are well-studied
The indication, dose, insurance coverage, and medical appropriateness depend on the specific medication and patient
However, both medication classes can cause gastrointestinal side effects, and semaglutide's effect on gastric emptying may require timing considerations for oral medications
However, lower doses may be sufficient depending on individual response
However, many anti-obesity agents that have entered human clinical trials have shown unacceptable adverse events
A research article on the effectiveness and safety of the non-peptide glucagon-like peptide- 1 (GLP- 1) receptor agonist Orforlipron than once daily oral therapy for weight reduction in adults with obesity